• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS neuroscience & therapeutics. >Rho Kinase Inhibitor Fasudil Protects against iβ/i‐Amyloid‐Induced Hippocampal Neurodegeneration in Rats
【24h】

Rho Kinase Inhibitor Fasudil Protects against iβ/i‐Amyloid‐Induced Hippocampal Neurodegeneration in Rats

机译：Rho激酶抑制剂法舒地尔预防大鼠β-淀粉样蛋白诱导的海马神经变性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary Background and purpose Alzheimer's disease ( AD ) is a progressive neurodegenerative disorder, and A β ‐induced neuronal damage is the major pathology of AD . There is increasing evidence that neuroinflammation induced by A β is also involved in the pathogenesis of AD . Fasudil is a Rho kinase inhibitor and has been reported to have neuroprotective effects. In this study, the main purpose is to investigate whether fasudil has beneficial effects on cognitive impairment and neuronal toxicity induced by A β . Methods and results In the present study, intracerebroventricular injection of A β 1–42 to rats resulted in marked cognitive impairment, severe neuronal damage, as well as increased IL ‐1 β , tumor necrosis factor alpha ( TNF ‐α) production, and NF ‐κB activation. Administration of fasudil significantly ameliorated the spatial learning and memory impairment, attenuated neuronal loss, and neuronal injury induced by A β 1–42. In addition, fasudil inhibited IL ‐1 β and TNF ‐α production and NF ‐κB activation in the rat brain. Conclusions Fasudil can protect against A β ‐induced hippocampal neurodegeneration by suppressing inflammatory response, suggesting that fasudil might be a promising agent for the prevention and treatment of inflammation‐related diseases, such as AD .
机译：概述背景和目的阿尔茨海默氏病（AD）是一种进行性神经退行性疾病，Aβ诱导的神经元损伤是AD的主要病理。越来越多的证据表明，Aβ引起的神经炎症也参与AD的发病机制。法舒地尔是一种Rho激酶抑制剂，据报道具有神经保护作用。在这项研究中，主要目的是研究法舒地尔对Aβ引起的认知障碍和神经元毒性是否具有有益作用。方法和结果在本研究中，脑室内注射Aβ1–42导致明显的认知障碍，严重的神经元损伤以及IL -1β升高，肿瘤坏死因子α（TNFα）产生和NF ‐κB激活。 Fasudil的使用可显着改善Aβ1–42引起的空间学习和记忆障碍，神经元减退和神经元损伤。此外，法舒地尔抑制大鼠脑中IL-1β和TNF-α的产生以及NF-κB的激活。结论法舒地尔可以通过抑制炎症反应来预防Aβ诱导的海马神经变性，这表明法舒地尔可能是预防和治疗炎症相关疾病（如AD）的有前途的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号